What is the TRiP(cast) score?
The Thrombosis Risk Prediction following Cast Immobilization score—often written L-TRiP(cast) (Leiden–Thrombosis Risk Prediction for patients with cast immobilization)—is a clinical prediction score developed to estimate the risk of a first venous thromboembolism (VTE) in adults who have lower-extremity plaster cast immobilization. Unlike broader VTE models built for the general population or for hospitalized medical inpatients, L-TRiP(cast) was constructed with explicit attention to the cast-specific context, including cast location and extent as a central driver of risk.
The published “clinical” version uses only environmental (readily ascertainable) predictors: it does not require coagulation assays, genetic testing, or other laboratory biomarkers. That design makes it practical for orthopedic clinics, emergency departments, fracture clinics, and primary care follow-up where rapid risk stratification is needed at the point of cast application.
Why VTE risk matters in cast immobilization
Immobilization of the leg reduces venous return and calf muscle pump activity; together with tissue injury from trauma or surgery, this shifts the hemostatic balance toward stasis and activation of coagulation pathways. Epidemiologic work has consistently identified cast immobilization as a meaningful VTE risk setting, yet the absolute incidence of symptomatic events across studies is heterogeneous, and anticoagulant prophylaxis carries a finite bleeding burden. As a result, guidelines and local practice patterns may differ, and clinicians often need a structured way to think about who is more likely to benefit from prophylaxis when balanced against individual bleeding risk and logistics of care.
A score such as L-TRiP(cast) is best understood as a decision-support layer: it summarizes multiple independent risk amplifiers into a single total that can be compared against an empirically studied cutoff. It does not diagnose DVT or PE, does not replace clinical gestalt, and should always be interpreted alongside mobility status, anticipated duration of immobilization, renal function, antiplatelet or anticoagulant use, concurrent injuries, and patient values.
How the score was built (conceptual overview)
The clinical model underlying L-TRiP(cast) was derived from a large population-based case–control resource and then translated into integer risk points using prespecified mappings from multivariable logistic regression coefficient magnitude to discrete weights. In plain terms, stronger independent associations in the model received larger point increments, bounded into tiers (for example, small effects map to one point, progressively larger effects map to two through five points).
The score was evaluated for discrimination in individuals with plaster cast immobilization of the lower extremity and also examined in external case–control settings. Reported performance should be interpreted as population-level discrimination (how well the score separates cases and controls), not as a guaranteed individual probability in your local health system. Calibration and event rates can shift with case mix, prophylaxis uptake, imaging intensity, and definitions of VTE.
Who is the intended patient population?
L-TRiP(cast) is framed for patients with plaster cast immobilization of the lower extremity in whom clinicians want a structured estimate of VTE risk. Typical scenarios include isolated fractures or soft-tissue injuries managed non-operatively or post-operatively with casting, where prolonged reduced ambulation is expected. The score’s factor list reflects comorbid and situational amplifiers that frequently co-occur with casting (recent hospitalization, recent surgery, infection, cancer history, hormonal exposures, thrombosis-related histories, and family history).
It is not designed for upper-extremity casts alone, spinal immobilization, multi-trauma populations excluded in the original modeling workflow, patients already therapeutically anticoagulated, or those in whom cast timing relative to prior VTE violates the study’s case definitions. When applying any risk model outside its derivation context, document the limitations explicitly in shared decision-making.
Scoring domains in detail
Age
Age contributes in tiered fashion: middle age and older age receive more points than youth. This aligns with the strong age dependence of first VTE in population data and the higher thrombotic burden seen across many immobilization studies. When using the calculator, choose the band that matches the patient’s current age at the time of cast placement.
Sex
Male sex receives a modest point increment in the published clinical score. Female-specific exposures (oral contraceptives and pregnancy or the puerperium) are handled as separate items because their prevalence and clinical relevance are sex-dependent. In practice, ensure that sex-specific items are only applied when clinically appropriate.
Body mass index (BMI)
Overweight and obesity categories add points with a higher tier for severe obesity. Adiposity-related prothrombotic changes, comorbidity burden, and reduced mobility patterns can cluster with casting, so BMI is both a mechanistically plausible contributor and a practical bedside variable.
Cast type and extent
Cast morphology is a major determinant in the score. A complete leg cast carries the largest weight, reflecting more extensive immobilization and hemodynamic consequences compared with more distal or less restrictive constructs. A lower leg cast occupies the next tier. Circular knee casts with a free ankle and isolated foot casts receive smaller—but still nonzero—weights, consistent with relatively less total limb encasement or retained ankle motion in some configurations.
Select exactly one cast category that best matches the patient’s actual device. If a patient transitions from one cast type to another during care, reassess the score at the time you are making prophylaxis decisions.
Active hormonal and pregnancy-related states
Current oral contraceptive use adds substantial points, reflecting estrogen-related thrombotic risk amplification in susceptible individuals. Pregnancy or puerperium similarly adds points, consistent with the hypercoagulable physiologic changes around gestation and the early postpartum period. These items should be applied based on current clinical status, not remote history.
Malignancy
Recent cancer history (as defined in the original data collection window) adds points. Malignancy increases VTE risk through tissue factor expression, inflammation, immobility, and treatment effects. Even when casting is for an orthopedic issue unrelated to cancer, the systemic risk state remains clinically salient.
Infection: pneumonia
Pneumonia is included as a comorbid insult that can activate coagulation and reduce reserve. In real-world use, apply this when pneumonia is a relevant active or recent diagnosis that plausibly overlaps the peri-cast risk window, using your clinical judgment on timing and severity.
Thrombosis-related history and family history
A history of superficial vein thrombosis contributes points, separate from prior deep vein thrombosis or pulmonary embolism in other instruments. A first-degree family history of VTE also contributes, capturing inherited and shared environmental predisposition that may not be fully known at the genotype level in routine practice.
Systemic comorbidity cluster
The score awards points for selected chronic conditions—rheumatoid arthritis, chronic kidney disease, chronic obstructive pulmonary disease, and multiple sclerosis—as grouped in the original instrument. These conditions associate with inflammation, immobility, infection risk, medication exposures, or hemoconcentration pathways that can raise thrombotic hazard in the setting of added immobilization.
Recent healthcare-associated immobilization and procedures
Points accrue for hospital admission within the prior three months, bedridden status within the prior three months, and surgery within the prior three months. Each captures a distinct pathway: acute illness severity and inpatient immobilization; prolonged home or facility confinement; and tissue injury, inflammation, and perioperative hemostatic activation. When more than one applies, the model allows them to accumulate because each encodes partially non-overlapping risk information at the population level.
Computing the total and interpreting the cutoff
The total L-TRiP(cast) score is the sum of points from all applicable domains. In the plaster cast subgroup described in the derivation work, investigators evaluated multiple thresholds; a commonly cited operational split uses 10 points or more versus fewer than 10 points. At that cutoff, a substantial fraction of cast patients fall into the higher-score stratum, and the reported operating characteristics reflect a tradeoff between sensitivity and specificity under a presumed background incidence suitable for predictive value calculations.
Clinicians should treat the cutoff as an epidemiologic anchor, not an automatic order for pharmacologic prophylaxis. A patient just below the threshold is not “zero risk,” and a patient above it is not destined to clot. The score’s purpose is to standardize documentation, prompt explicit risk–benefit reasoning, and support consistent team communication—especially when discussing prophylaxis with patients who are ambivalent about injections or tablets.
Integration with bleeding risk and operational constraints
Before starting prophylaxis, consider bleeding risk (recent surgery or intracranial injury, gastrointestinal bleeding history, thrombocytopenia, uncontrolled hypertension, concurrent antiplatelet agents, renal impairment affecting drug clearance, and patient adherence). Also consider practical factors: expected cast duration, ability to return for monitoring, availability of low-molecular-weight heparin versus oral agents per local protocol, and whether mechanical measures are adequate or adjunctive.
For patients in whom pharmacologic prophylaxis is contraindicated, the score may still be useful to flag heightened surveillance needs and patient education about alarm symptoms for DVT and PE.
Documentation, follow-up, and patient education
When you use L-TRiP(cast), document the cast type, the score total, the threshold comparison, and the rationale for prophylaxis or watchful management. Provide patients with clear instructions on calf swelling, new chest pain, dyspnea, hemoptysis, syncope, and unilateral leg discoloration, emphasizing that models do not replace urgent evaluation when symptoms arise.
Limitations every clinician should keep in mind
- Case-mix shift: Derivation and validation cohorts may differ from your center’s trauma profile, age distribution, and baseline prophylaxis practices.
- Outcome definition and ascertainment: Symptomatic versus screening-detected VTE, intensity of imaging, and follow-up duration change apparent incidence and model utility.
- Missing covariates: Important factors (prior DVT/PE, known thrombophilia, weight-bearing status, cast duration) may not be fully captured; clinical judgment remains primary.
- Treatment penetration: If many high-risk patients already receive prophylaxis, observed event rates in treated cohorts will underestimate untreated risk, complicating post hoc benchmarking.
- Score ≠ probability: The total points summarize relative risk stratification; translating to an individualized probability requires external calibration and local epidemiology.